|
ES2357505T3
(es)
|
2002-09-11 |
2011-04-27 |
Genentech, Inc. |
Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
|
|
US20070054360A1
(en)
|
2005-05-12 |
2007-03-08 |
Zeren Gao |
Compositions and methods for modulating immune responses
|
|
MX2010011088A
(es)
|
2008-04-09 |
2010-11-05 |
Genentech Inc |
Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
|
|
AU2010229994B2
(en)
|
2009-03-25 |
2016-08-18 |
Genentech, Inc. |
Anti-FGFR3 antibodies and methods using same
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
HRP20190044T1
(hr)
|
2011-09-23 |
2019-02-22 |
Oncomed Pharmaceuticals, Inc. |
Agensi koji vežu vegf/dll4 i njihove uporabe
|
|
WO2014089495A1
(en)
|
2012-12-07 |
2014-06-12 |
Chemocentryx, Inc. |
Diazole lactams
|
|
DK3021869T3
(da)
*
|
2013-07-16 |
2020-09-21 |
Hoffmann La Roche |
Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
US10618963B2
(en)
|
2014-03-12 |
2020-04-14 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
US10519237B2
(en)
|
2014-03-12 |
2019-12-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
ES3040431T3
(en)
|
2014-03-12 |
2025-10-31 |
Yeda Res & Dev |
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
|
|
US9394365B1
(en)
|
2014-03-12 |
2016-07-19 |
Yeda Research And Development Co., Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
|
|
ME03558B
(me)
|
2014-03-14 |
2020-07-20 |
Novartis Ag |
Molekuli anti-lag-3 antiтela i njihove upotrebe
|
|
US20170107300A1
(en)
*
|
2014-03-21 |
2017-04-20 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
JP6592505B2
(ja)
|
2014-04-24 |
2019-10-16 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
KR102050082B1
(ko)
|
2014-08-19 |
2019-11-29 |
머크 샤프 앤드 돔 코포레이션 |
항-tigit 항체
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
RU2017119428A
(ru)
*
|
2014-11-06 |
2018-12-06 |
Дженентек, Инк. |
Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
|
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
WO2016134234A1
(en)
*
|
2015-02-19 |
2016-08-25 |
Bioclin Therapeutics, Inc. |
Methods, compositions, and kits for treatment of cancer
|
|
CA2976926A1
(en)
|
2015-02-19 |
2016-08-25 |
Compugen Ltd. |
Anti-pvrig antibodies and methods of use
|
|
DK3259597T3
(da)
|
2015-02-19 |
2022-05-09 |
Compugen Ltd |
Pvrig-polypeptider og fremgangsmåder til behandling
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
SI3297438T1
(sl)
|
2015-05-21 |
2022-03-31 |
Chemocentryx, Inc. |
CCR2 modulatorji
|
|
TWI715587B
(zh)
*
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
CN107849144B
(zh)
|
2015-05-29 |
2021-09-17 |
艾吉纳斯公司 |
抗-ctla-4抗体及其使用方法
|
|
LT3303396T
(lt)
|
2015-05-29 |
2023-01-10 |
Bristol-Myers Squibb Company |
Antikūnai prieš ox40 ir jų panaudojimo būdai
|
|
JO3620B1
(ar)
*
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
US10766957B2
(en)
|
2015-08-14 |
2020-09-08 |
Merck Sharp & Dohme Corp |
Anti-TIGIT antibodies
|
|
CN108026533B
(zh)
*
|
2015-09-01 |
2021-08-17 |
中央研究院 |
拮抗性pdl1适体及其在癌症治疗中的应用
|
|
HK1257840A1
(zh)
|
2015-09-01 |
2019-11-01 |
Agenus Inc. |
抗-pd-1抗体及其使用方法
|
|
ES2924071T3
(es)
*
|
2015-09-02 |
2022-10-04 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
|
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
|
EP3353210B8
(en)
|
2015-09-25 |
2024-12-18 |
F. Hoffmann-La Roche AG |
Anti-tigit antibodies and methods of use
|
|
SG10201912736UA
(en)
*
|
2015-10-01 |
2020-02-27 |
Potenza Therapeutics Inc |
Anti-tigit antigen-binding proteins and methods of use thereof
|
|
PE20180773A1
(es)
|
2015-10-02 |
2018-05-07 |
Hoffmann La Roche |
Anticuerpos biespecificos para pd1 y tim3
|
|
SI3370768T1
(sl)
|
2015-11-03 |
2022-04-29 |
Janssen Biotech, Inc. |
Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
|
|
EP3383430A4
(en)
|
2015-12-02 |
2019-12-18 |
Agenus Inc. |
ANTIBODIES AND METHOD FOR USE THEREOF
|
|
SI3394103T1
(sl)
|
2015-12-22 |
2023-10-30 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija protiteles proti-PD-1 in bispecifičnih protiteles proti-CD20/proti-CD3 za zdravljenje raka
|
|
EP3400963A4
(en)
*
|
2016-01-08 |
2019-08-21 |
Taiho Pharmaceutical Co., Ltd. |
Antitumor agent-containing immunomodulator and antitumor enhancer
|
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
|
EP3407820A4
(en)
|
2016-01-26 |
2019-11-06 |
Cyberdontics, Inc. |
Automated dental treatment system
|
|
MX2018010445A
(es)
*
|
2016-03-01 |
2019-10-17 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos especificos del receptor de poliovirus humano (rvp).
|
|
IL261188B
(en)
|
2016-03-04 |
2022-08-01 |
Jn Biosciences Llc |
An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
CN109153719B
(zh)
*
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
PL3439653T3
(pl)
*
|
2016-04-07 |
2021-07-05 |
Chemocentryx, Inc. |
Zmniejszenie obciążenia guzem przez podawanie antagonistów ccr1 w skojarzeniu z inhibitorami pd-1 lub inhibitorami pd-l1
|
|
EP3443000B1
(en)
|
2016-04-15 |
2025-11-12 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
KR20190003958A
(ko)
*
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
|
IL262227B
(en)
*
|
2016-04-20 |
2022-07-01 |
Univ Tsukuba |
Regulatory t cell activator, and use thereof
|
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
EP3494219A1
(en)
*
|
2016-08-03 |
2019-06-12 |
Aalborg Universitet |
ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
|
|
IL301682B2
(en)
*
|
2016-08-17 |
2025-06-01 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
WO2018041120A1
(en)
*
|
2016-08-31 |
2018-03-08 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animal with human or chimeric tigit
|
|
CN107815467B
(zh)
|
2016-08-31 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化基因改造动物模型的制备方法及应用
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
US11230596B2
(en)
*
|
2016-11-30 |
2022-01-25 |
Mereo Biopharma 5, Inc. |
Methods for treatment of cancer comprising TIGIT-binding agents
|
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
|
FI3551660T3
(fi)
|
2016-12-07 |
2023-12-11 |
Agenus Inc |
Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
|
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
KR20190095921A
(ko)
*
|
2016-12-12 |
2019-08-16 |
제넨테크, 인크. |
항-pd-l1 항체 및 안티안드로겐을 사용하여 암을 치료하는 방법
|
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
WO2018136553A1
(en)
|
2017-01-18 |
2018-07-26 |
Genentech, Inc. |
Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
MA47694A
(fr)
*
|
2017-02-28 |
2021-05-19 |
Seagen Inc |
Anticorps anti-tigit
|
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
JOP20190203A1
(ar)
*
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TW202402800A
(zh)
|
2017-05-01 |
2024-01-16 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體類和使用彼等之方法
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
US20200354453A1
(en)
*
|
2017-05-02 |
2020-11-12 |
Merck Sharp & Dohme Corp. |
Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
|
CN110799213A
(zh)
|
2017-06-01 |
2020-02-14 |
康姆普根有限公司 |
三联组合抗体疗法
|
|
JP7657023B2
(ja)
|
2017-06-09 |
2025-04-04 |
プロビデンス ヘルス アンド サービシーズ－オレゴン |
がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
EP3641814A4
(en)
|
2017-06-19 |
2021-06-23 |
Medicenna Therapeutics Inc. |
USES AND METHODS FOR IL-2 SUPERAGONISTS AND AGONISTS AND FUSIONS THEREOF
|
|
EP3645738A4
(en)
*
|
2017-06-25 |
2021-08-18 |
Systimmune, Inc. |
ANTI-PD-L1 ANTIBODIES AND METHODS FOR PREPARATION AND USE
|
|
IL272227B2
(en)
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
US20230192845A1
(en)
*
|
2017-08-11 |
2023-06-22 |
Blink Biomedical Sas |
Cd96-binding agents as immunomodulators
|
|
CN113004417A
(zh)
*
|
2017-09-07 |
2021-06-22 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
EP3689909A4
(en)
|
2017-09-29 |
2021-12-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Tigit antibody, antigen-binding fragment thereof, and medical use thereof
|
|
CN109575140B
(zh)
*
|
2017-09-29 |
2021-02-23 |
北京比洋生物技术有限公司 |
靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
KR20240151258A
(ko)
|
2017-10-11 |
2024-10-17 |
오리진 온콜로지 리미티드 |
3-치환된 1,2,4-옥사다이아졸의 결정질 형태
|
|
EA202090746A1
(ru)
|
2017-11-03 |
2020-08-17 |
Ориджен Дискавери Текнолоджис Лимитед |
Двойные ингибиторы путей tim-3 и pd-1
|
|
CN111386128A
(zh)
|
2017-11-06 |
2020-07-07 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的联合疗法
|
|
CN108254557B
(zh)
*
|
2017-12-26 |
2019-05-31 |
首都医科大学附属北京地坛医院 |
用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统
|
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
TWI877769B
(zh)
|
2017-12-30 |
2025-03-21 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US20190269664A1
(en)
|
2018-01-08 |
2019-09-05 |
Chemocentryx, Inc. |
Methods of treating solid tumors with ccr2 antagonists
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
EP3568415B1
(en)
*
|
2018-02-06 |
2025-01-22 |
I-Mab Biopharma (Hangzhou) Co., Ltd. |
Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
|
|
CA3090236A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
KR102832460B1
(ko)
|
2018-02-20 |
2025-07-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
|
|
AU2019225249A1
(en)
*
|
2018-02-26 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
|
|
MX2020008795A
(es)
|
2018-02-28 |
2020-10-08 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
US20210379024A1
(en)
|
2018-03-14 |
2021-12-09 |
Aurigene Discovery Technologies Limited |
Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds
|
|
CN108546299B
(zh)
*
|
2018-03-29 |
2019-09-24 |
中国人民解放军军事科学院军事医学研究院 |
解除pd-1对机体免疫抑制的靶向分子
|
|
CN108546298B
(zh)
*
|
2018-03-29 |
2021-05-14 |
中国人民解放军军事科学院军事医学研究院 |
一种特异性结合pd-1的单克隆抗体
|
|
WO2019215512A1
(en)
|
2018-05-10 |
2019-11-14 |
Cyberdontics Inc. |
Automated dental drill
|
|
SG11202011461TA
(en)
|
2018-06-01 |
2020-12-30 |
Compugen Ltd |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
|
WO2020006516A1
(en)
|
2018-06-29 |
2020-01-02 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
AU2019310803B2
(en)
|
2018-07-25 |
2022-11-03 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-TIGIT antibody and uses thereof
|
|
MX2021001527A
(es)
|
2018-08-08 |
2021-06-15 |
Dragonfly Therapeutics Inc |
Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MA53293A
(fr)
|
2018-08-08 |
2021-11-17 |
Dragonfly Therapeutics Inc |
Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
|
|
AU2019324170A1
(en)
|
2018-08-23 |
2021-02-18 |
Seagen, Inc. |
Anti-TIGIT antibodies
|
|
US11312963B2
(en)
*
|
2018-10-18 |
2022-04-26 |
Synerk Inc. |
Compositions and methods for inhibiting TIGIT gene expression
|
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
|
CN109448790B
(zh)
*
|
2018-11-19 |
2021-11-09 |
上海科技大学 |
一种确定肿瘤免疫治疗标志物的存储介质、设备及装置
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
EP3927728A2
(en)
|
2019-02-21 |
2021-12-29 |
Xencor, Inc. |
Untargeted and targeted il-10 fc-fusion proteins
|
|
WO2020206033A1
(en)
*
|
2019-04-02 |
2020-10-08 |
Kenjockety Biotechnology, Inc. |
Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
|
|
EP3725370A1
(en)
|
2019-04-19 |
2020-10-21 |
ImmunoBrain Checkpoint, Inc. |
Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
|
|
TWI760751B
(zh)
*
|
2019-05-29 |
2022-04-11 |
美商美國禮來大藥廠 |
Tigit及pd-1/tigit-結合分子
|
|
CN110128550B
(zh)
*
|
2019-05-30 |
2023-01-13 |
南京惟亚德生物医药有限公司 |
一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
|
|
WO2020263312A1
(en)
|
2019-06-28 |
2020-12-30 |
Gensun Biopharma, Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
US20220363754A1
(en)
|
2019-07-15 |
2022-11-17 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-tigit antibodies and application thereof
|
|
US20220251194A1
(en)
*
|
2019-07-30 |
2022-08-11 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
JP7122354B2
(ja)
|
2019-09-24 |
2022-08-19 |
財團法人工業技術研究院 |
抗ｔｉｇｉｔ抗体および使用方法
|
|
PH12022550671A1
(en)
|
2019-09-27 |
2023-05-29 |
Glaxosmithkline Ip Dev Ltd |
Antigen binding proteins
|
|
JP2022548978A
(ja)
*
|
2019-09-27 |
2022-11-22 |
ジェネンテック， インコーポレイテッド |
薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
|
|
WO2021086889A1
(en)
*
|
2019-10-29 |
2021-05-06 |
Chinook Therapeutics, Inc. |
Methods and compositions for treatment of cancer and infectious diseases
|
|
US20230057899A1
(en)
|
2019-12-05 |
2023-02-23 |
Compugen Ltd. |
Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
|
|
EP4106813A4
(en)
|
2020-02-21 |
2024-03-27 |
MacroGenics, Inc. |
CD137 BINDING MOLECULES AND THEIR USES
|
|
CN115003333A
(zh)
|
2020-03-13 |
2022-09-02 |
江苏恒瑞医药股份有限公司 |
Pvrig结合蛋白及其医药用途
|
|
CN113563470B
(zh)
*
|
2020-04-29 |
2023-02-10 |
广州昂科免疫生物技术有限公司 |
结合tigit抗原的抗体及其制备方法与应用
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
CN114507284B
(zh)
|
2020-05-09 |
2023-05-26 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
CR20220611A
(es)
|
2020-06-02 |
2023-06-07 |
Arcus Biosciences Inc |
Anticuerpos anti-tigit
|
|
US20210395366A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
MX2023000197A
(es)
|
2020-07-07 |
2023-02-22 |
BioNTech SE |
Arn terapeutico para el cancer positivo para vph.
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
CN112190689B
(zh)
*
|
2020-08-25 |
2022-12-09 |
沣潮医药科技（上海）有限公司 |
Tigit免疫粘附素在调控肿瘤免疫及调节血管生成产品中的应用
|
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
|
KR102647295B1
(ko)
*
|
2020-09-03 |
2024-03-14 |
한국과학기술연구원 |
암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도
|
|
EP4208122A4
(en)
|
2020-09-03 |
2024-09-11 |
Perceptive Technologies, Inc. |
METHOD AND DEVICE FOR CNA ANALYSIS OF DENTAL ANATOMY
|
|
CN114539418A
(zh)
|
2020-11-26 |
2022-05-27 |
上海华奥泰生物药业股份有限公司 |
双特异性抗体及其用途
|
|
JP2024508207A
(ja)
|
2020-12-02 |
2024-02-26 |
ブイアイビー ブイゼットダブリュ |
がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
EP4293045A4
(en)
|
2021-01-14 |
2024-12-11 |
Shanghai Junshi Biosciences Co., Ltd. |
PHARMACEUTICAL COMPOSITION OF ANTI-TIGIT ANTIBODY AND ITS APPLICATION
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
IL307556A
(en)
*
|
2021-04-09 |
2023-12-01 |
Seagen Inc |
Cancer treatment methods using antibodies against TIGIT
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
JP2024527049A
(ja)
|
2021-07-28 |
2024-07-19 |
ジェネンテック， インコーポレイテッド |
がんを治療するための方法及び組成物
|
|
US20250064794A1
(en)
*
|
2021-08-10 |
2025-02-27 |
Eisai R&D Management Co., Ltd. |
A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
|
|
TW202328195A
(zh)
|
2021-09-15 |
2023-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合ｐｄ－１的蛋白及其醫藥用途
|
|
US20240376207A1
(en)
|
2021-09-15 |
2024-11-14 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody
|
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
IL313018A
(en)
|
2021-12-17 |
2024-07-01 |
Tnax Biopharma Corp |
Humanized anti-dnam-1 antibody
|
|
JP2025509832A
(ja)
|
2022-03-15 |
2025-04-11 |
コンピュジェン リミテッド |
Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
AU2023393653A1
(en)
|
2022-12-14 |
2025-05-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
CN120826478A
(zh)
|
2023-03-06 |
2025-10-21 |
基因泰克公司 |
用于非小细胞肺癌的预后和治疗方法
|
|
CN116444675B
(zh)
*
|
2023-05-11 |
2023-12-22 |
亲和(武汉)生命科技有限责任公司 |
一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025016012A1
(en)
*
|
2023-07-14 |
2025-01-23 |
Genor Biopharma Co., Ltd. |
Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|